In 2018 and 2019, Centrient successfully launched new finished dosage forms (FDFs). In particular, the launch of our Rosuvastatin FDF in January 2018 was a major success. We were able to introduce this generic medicine to several European markets right on time, following the expiration of the innovator product’s patent.

We followed this with the launch of our Atorvastatin film-coated tablets in June 2018. The tablets we offered in two new strengths, 15mg and 30mg, that had been previously unavailable in several markets. Our newest product, Caspofungin, was also added to our anti-fungal portfolio and introduced to hospitals in several countries.

In 2019, we launched 45 medicinal products in the European Union and Switzerland and added FDF supply in six additional countries. This included the introduction of Amoxicillin powder for oral suspension to the Scandinavian market. With these product launches, we have been able to offer FDFs in statins, anti-fungals and antibiotics across our global network. These activities confirm our status as a full-service generics pharmaceutical company.

We are also taking steps to strengthen security of supply, by adding more than one API supplier or manufacturer and by expanding into new countries and markets. Our Regulatory Affairs department offers customers additional services, such as assistance with their regulatory affairs strategy, as well as operational support in case changes need to be made.